Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

Structure, Functions and Selective Inhibitors of HDAC6

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Histone deacetylase 6 in cancer

Curriculum vitae of HDAC6 in solid tumors

Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances

Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue

Do Biological Activities of Selective Histone Deacetylase 6 (HDAC6) Inhibitors Rely on the Modification of Cap Group?

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

HDAC8 as a target in drug discovery: Function, structure and design

Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling

Targeting histone deacetylases for cancer therapy: Trends and challenges

HDAC11: A novel target for improved cancer therapy

Design, Synthesis, and Antiproliferative Activity of Selective Histone Deacetylases 6 Inhibitors Containing a Tetrahydropyridopyrimidine Scaffold

Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors

Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1h-indole Fragment: Virtual Screening, Rational Design, and Biological Evaluation